Edgewise Therapeutics, Inc. — Q2 2021 Form 10-Q
Business context and reporting period. This clinical-stage biopharmaceutical company reported for the quarter and six months ended June 30, 2021. Its lead candidate, EDG-5506, was in Phase 1 clinical development for dystrophinopathies; EDG-6289, EDG-002 and EDG-003 remained earlier-stage programs. The company had no approved products and generated no revenue.
Financial results and liquidity
| Metric | Q2 2021 | Q2 2020 | Six months 2021 | Six months 2020 |
|---|---|---|---|---|
| Revenue | None | None | None | None |
| Research and development expense | $7.9 million | $3.6 million | $13.2 million | $6.6 million |
| General and administrative expense | $2.6 million | $0.3 million | $4.1 million | $0.6 million |
| Net loss | $10.4 million | $4.0 million | $17.2 million | $7.1 million |
| Net loss per share, basic and diluted | $0.21 | $7.43 | $0.67 | $14.98 |
| Operating cash used | Not provided for quarter | Not provided for quarter | $15.8 million | $6.7 million |
- At June 30, 2021, cash and cash equivalents were $50.4 million and available-for-sale marketable securities were $248.7 million, totaling approximately $299.2 million. Current assets were $303.0 million; current liabilities were $6.7 million.
- Six-month investing cash outflow was $224.7 million, primarily reflecting purchases of marketable securities ($231.8 million), partly offset by $7.2 million in maturities. Financing provided $186.1 million, principally from the IPO.
- The company had no debt outstanding. Profit margins are not meaningful because it had no revenue and incurred operating losses.
- Accumulated deficit was $51.3 million. The filing reported $296.8 million of stockholders’ equity at quarter-end.
Material changes versus comparable periods
- Q2 operating expenses increased $6.5 million year over year. R&D rose $4.2 million, mainly from EDG-5506 Phase 1 trial costs, other discovery and preclinical work, and higher staffing. G&A rose $2.3 million, including public-company costs, additional personnel, directors’ and officers’ insurance, and professional services.
- Six-month net loss increased $10.0 million year over year, while operating cash use increased $9.1 million.
- In March 2021, the company completed its IPO, selling 12.65 million shares at $16.00 per share and receiving approximately $186.1 million net. Existing preferred stock converted into 35.6 million common shares; 49.3 million common shares were outstanding at June 30.
- Reported loss per share is not directly comparable year over year because the weighted-average share count increased substantially following the IPO and preferred-stock conversion.
Outlook, commentary and risks
- Management expected R&D spending to rise as EDG-5506 advances and other programs develop, and anticipated higher public-company and staffing costs. The filing gives no revenue or earnings guidance.
- Management stated that available cash and marketable securities should fund planned operations for at least 24 months. The financial-statement liquidity note separately says funds are sufficient for at least the next 12 months; the difference should be clarified.
- COVID-19 had disrupted trial enrollment, data collection and supply activities. The company also described switching EDG-5506 manufacturing from an international supplier to a U.S. supplier to reduce disruption risk.
- The filing reported dose-limiting somnolence at 135 mg in the EDG-5506 single-ascending-dose trial. Clinical outcomes remain uncertain; the candidate was early in development and the company depended on third parties for trials and manufacturing.
- Management highlighted substantial financing needs beyond the stated near-term runway, clinical and regulatory uncertainty, competition, and intellectual-property risks. It disclosed that its patent portfolio was pending prosecution and that it owned no issued patents at the time of the filing.
- No material legal proceedings were pending or threatened. Disclosure controls were assessed as effective at a reasonable-assurance level; no material change in internal control over financial reporting was reported.
Important facts for investors to verify
- Why the stated cash runway differs between the liquidity note (at least 12 months) and management’s discussion (at least 24 months), and what assumptions underpin the estimate.
- Subsequent EDG-5506 trial results, including safety findings, enrollment progress and the significance of somnolence at 135 mg.
- Progress in establishing reliable manufacturing supply after the supplier change, and any resulting clinical or cost delays.
- Status and scope of patent applications, including potential third-party intellectual-property exposure.
- Potential share-supply and dilution effects, including the scheduled September 2021 IPO lock-up expiration and outstanding equity awards.